Quoted from http://www.bloomberg.com/apps/news?pid=20601202&sid=aNwFCG0.ZVII
Glaxo Linked Birth Defect of Fetus to Paxil, Ex-Executive Says
By Jef Feeley and Sophia Pearson
Sept. 18 (Bloomberg) -- Officials of GlaxoSmithKline Plc, the U.K.’s largest drugmaker, said in 2001 that a birth defect in the fetus of a woman taking its Paxil antidepressant likely was linked to the drug, according to court testimony.
After analyzing a 2001 e-mail from a Paxil user who aborted her fetus because it had a heart defect, Glaxo officials noted in company files they were “almost certain” the drug was related to the problem, Jane Nieman, a former Glaxo drug-safety executive, told a Pennsylvania jury.
“I don’t know who made that assessment, but it’s there,” Nieman testified in a videotaped deposition played yesterday for jurors. Nieman’s testimony came in the trial of another Paxil user’s lawsuit over birth defects suffered by her now 3-year-old son.
The state-court trial in Philadelphia is the first of more than 600 cases alleging Glaxo knew Paxil caused birth defects and hid those risks to increase profits. The drug, approved for U.S. use in 1992, generated about $942 million in sales last year, 2.1 percent of Glaxo’s total revenue....
The case is Kilker v. SmithKline Beecham Corp. dba GlaxoSmithKline, 2007-001813, Court of Common Pleas, Philadelphia County, Pennsylvania (Philadelphia).